June 20, 2011 -- The SFDA has ordered GlaxoSmithKline to withdraw an antibiotic from China after trace elements of a banned substance were found in samples. The drug is amoxicillin and clavulanate potassium. The SFDA has been under pressure to take action after Taiwan and Hong Kong banned the drug two weeks ago. SFDA tests of the drug showed small amounts – the SFDA did not say how much – of an additive included in plastics to make them more flexible. From a larger perspective, the incident is one more skirmish in the long-running battle between China and the West over drug safety. More details....
Stock Symbol: (NYSE: GSK)
